UBS Group’s Amgen AMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.11B | Sell |
3,148,040
-956,484
| -23% | -$341M | 0.17% | 116 |
|
|
2025
Q4 | $1.34B | Sell |
4,104,524
-128,230
| -3% | -$40.7M | 0.22% | 75 |
|
|
2025
Q3 | $1.19B | Sell |
4,232,754
-344,914
| -8% | -$100M | 0.19% | 84 |
|
|
2025
Q2 | $1.28B | Buy |
4,577,668
+91,273
| +2% | +$25.9M | 0.22% | 73 |
|
|
2025
Q1 | $1.4B | Buy |
4,486,395
+418,781
| +10% | +$124M | 0.26% | 58 |
|
|
2024
Q4 | $1.06B | Buy |
4,067,614
+460,876
| +13% | +$137M | 0.2% | 90 |
|
|
2024
Q3 | $1.16B | Sell |
3,606,738
-109,933
| -3% | -$36M | 0.25% | 67 |
|
|
2024
Q2 | $1.16B | Sell |
3,716,671
-30,939
| -0.8% | -$9.09M | 0.29% | 60 |
|
|
2024
Q1 | $1.07B | Buy |
3,747,610
+387,082
| +12% | +$113M | 0.27% | 59 |
|
|
2023
Q4 | $968M | Buy |
3,360,528
+444,008
| +15% | +$121M | 0.29% | 60 |
|
|
2023
Q3 | $784M | Sell |
2,916,520
-334,740
| -10% | -$83.5M | 0.27% | 66 |
|
|
2023
Q2 | $722M | Sell |
3,251,260
-527,937
| -14% | -$123M | 0.24% | 87 |
|
|
2023
Q1 | $914M | Sell |
3,779,197
-63,945
| -2% | -$15.7M | 0.33% | 57 |
|
|
2022
Q4 | $1.01B | Buy |
3,843,142
+486,697
| +15% | +$130M | 0.38% | 49 |
|
|
2022
Q3 | $757M | Sell |
3,356,445
-224,009
| -6% | -$54.3M | 0.33% | 55 |
|
|
2022
Q2 | $871M | Sell |
3,580,454
-96,915
| -3% | -$23.7M | 0.36% | 50 |
|
|
2022
Q1 | $889M | Sell |
3,677,369
-104,939
| -3% | -$24.1M | 0.3% | 68 |
|
|
2021
Q4 | $851M | Sell |
3,782,308
-52,893
| -1% | -$11.2M | 0.24% | 83 |
|
|
2021
Q3 | $816M | Buy |
3,835,201
+108,502
| +3% | +$25M | 0.26% | 78 |
|
|
2021
Q2 | $908M | Buy |
3,726,699
+346,659
| +10% | +$85.3M | 0.29% | 67 |
|
|
2021
Q1 | $841M | Buy |
3,380,040
+137,148
| +4% | +$32.7M | 0.28% | 69 |
|
|
2020
Q4 | $746M | Buy |
3,242,892
+897,628
| +38% | +$207M | 0.25% | 86 |
|
|
2020
Q3 | $596M | Buy |
2,345,264
+84,739
| +4% | +$21M | 0.22% | 107 |
|
|
2020
Q2 | $533M | Sell |
2,260,525
-227,734
| -9% | -$52M | 0.23% | 104 |
|
|
2020
Q1 | $504M | Sell |
2,488,259
-525,866
| -17% | -$115M | 0.24% | 92 |
|
|
2019
Q4 | $727M | Buy |
3,014,125
+251,813
| +9% | +$55.5M | 0.25% | 90 |
|
|
2019
Q3 | $535M | Buy |
2,762,312
+242,496
| +10% | +$46.5M | 0.21% | 113 |
|
|
2019
Q2 | $464M | Buy |
2,519,816
+104,407
| +4% | +$18.7M | 0.18% | 129 |
|
|
2019
Q1 | $459M | Buy |
2,415,409
+204,043
| +9% | +$39M | 0.19% | 125 |
|
|
2018
Q4 | $430M | Sell |
2,211,366
-400,662
| -15% | -$78.2M | 0.2% | 120 |
|
|
2018
Q3 | $541M | Sell |
2,612,028
-198,823
| -7% | -$39.2M | 0.21% | 109 |
|
|
2018
Q2 | $519M | Buy |
2,810,851
+39,753
| +1% | +$7.03M | 0.22% | 104 |
|
|
2018
Q1 | $472M | Sell |
2,771,098
-59,392
| -2% | -$10.9M | 0.2% | 115 |
|
|
2017
Q4 | $492M | Buy |
2,830,490
+581,356
| +26% | +$103M | 0.2% | 124 |
|
|
2017
Q3 | $419M | Sell |
2,249,134
-130,337
| -5% | -$23.1M | 0.19% | 120 |
|
|
2017
Q2 | $410M | Buy |
2,379,471
+72,102
| +3% | +$11.7M | 0.21% | 114 |
|
|
2017
Q1 | $379M | Buy |
2,307,369
+320,932
| +16% | +$53.3M | 0.21% | 113 |
|
|
2016
Q4 | $290M | Buy |
1,986,437
+8,812
| +0.4% | +$1.33M | 0.16% | 151 |
|
|
2016
Q3 | $330M | Buy |
1,977,625
+180,125
| +10% | +$30.5M | 0.2% | 118 |
|
|
2016
Q2 | $273M | Buy |
1,797,500
+83,992
| +5% | +$13.1M | 0.17% | 140 |
|
|
2016
Q1 | $257M | Buy |
1,713,508
+98,732
| +6% | +$14.7M | 0.17% | 138 |
|
|
2015
Q4 | $262M | Buy |
1,614,776
+303,444
| +23% | +$47.7M | 0.17% | 129 |
|
|
2015
Q3 | $181M | Sell |
1,311,332
-295,533
| -18% | -$46.6M | 0.13% | 180 |
|
|
2015
Q2 | $247M | Sell |
1,606,865
-149,086
| -8% | -$23.9M | 0.16% | 148 |
|
|
2015
Q1 | $281M | Sell |
1,755,951
-307,826
| -15% | -$48.5M | 0.19% | 119 |
|
|
2014
Q4 | $329M | Buy |
+2,063,777
| New | +$322M | 0.23% | 89 |
|
Other funds holding AMGN
VCM
VPM
UBS Group's AMGN Position: Q1 2026 in Review
UBS Group reduced its Amgen (AMGN) stake by 23% in Q1 2026, selling an estimated $341M and leaving 3,148,040 shares worth $1.11B. The position accounts for 0.17% of the portfolio, ranked #116.
UBS Group first reported a position in AMGN in Q4 2014 and has held it in 46 quarters since. The position peaked at $1.4B in Q1 2025. 3,129 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.
- UBS Group held 3,148,040 shares of Amgen worth $1.11B as of Q1 2026.
- UBS Group sold 956,484 Amgen shares in Q1 2026, an estimated $341M.
- Amgen made up 0.17% of UBS Group's portfolio in Q1 2026, its #116 holding.
- UBS Group first reported a position in Amgen in Q4 2014 and has held it in 46 quarters since.
- UBS Group's Amgen position peaked at $1.4B in Q1 2025.
- 3,129 funds tracked by Wall St. Rank held Amgen as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.